INSPIRE: INnovative SABR for Prostate Cancer All IREland

This is a Phase II, single arm, multi-centre, prospective clinical trial evaluating next generation Stereotactic Ablative Radiotherapy (SABR) for low, intermediate, and eligible high-risk prostate cancer. Eligible patients will receive next generation prostate SABR incorporating toxicity reduction strategies

NCT Number	NCT07552168
Lead Sponsor	Cancer Trials Ireland
Conditions	Prostate Adenocarcinoma
Enrollment	136 participants
Start Date	2026-04-23
Primary Completion	2030-09 (estimated)
Study Completion	2034-11 (estimated)
Updated on ClinicalTrials.gov	2026-07-06